JP4719144B2 - ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 - Google Patents
ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 Download PDFInfo
- Publication number
- JP4719144B2 JP4719144B2 JP2006505892A JP2006505892A JP4719144B2 JP 4719144 B2 JP4719144 B2 JP 4719144B2 JP 2006505892 A JP2006505892 A JP 2006505892A JP 2006505892 A JP2006505892 A JP 2006505892A JP 4719144 B2 JP4719144 B2 JP 4719144B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- mmol
- ethyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*(CCC1CC2)CC1C(CC1)C2C2C1CICCC2 Chemical compound C*(CCC1CC2)CC1C(CC1)C2C2C1CICCC2 0.000 description 12
- KJZGKEBTVBJPGW-LIGHTNSPSA-N CC(CC1)(C(CC2)C(CCc3c4)C1c3cc(C)c4OCc1ccccc1)[C@H]2OCCOC Chemical compound CC(CC1)(C(CC2)C(CCc3c4)C1c3cc(C)c4OCc1ccccc1)[C@H]2OCCOC KJZGKEBTVBJPGW-LIGHTNSPSA-N 0.000 description 1
- NTAAYXYMXREDHO-YLOYLXSZSA-N CCC1=CC(C(CC2)[C@@H](CC3)C(CC4)[C@@]2(C)[C@H]4C(C)C#N)C3C=C1O Chemical compound CCC1=CC(C(CC2)[C@@H](CC3)C(CC4)[C@@]2(C)[C@H]4C(C)C#N)C3C=C1O NTAAYXYMXREDHO-YLOYLXSZSA-N 0.000 description 1
- ULWPFRRVBLSYOS-CXUHLZMHSA-N CCc(cc(C(CC1)C(CC2)C(CC3)C1(C)/C3=C/CO)c2c1)c1O Chemical compound CCc(cc(C(CC1)C(CC2)C(CC3)C1(C)/C3=C/CO)c2c1)c1O ULWPFRRVBLSYOS-CXUHLZMHSA-N 0.000 description 1
- FFUFRNDKVZDNFW-UHFFFAOYSA-N CCc(cc(C(CC1)C(CC2)C(CC3)C1(C)C3O)c2c1)c1OCOC Chemical compound CCc(cc(C(CC1)C(CC2)C(CC3)C1(C)C3O)c2c1)c1OCOC FFUFRNDKVZDNFW-UHFFFAOYSA-N 0.000 description 1
- LEMLOZUONYRJOT-LRUVZNEXSA-N CCc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)C3OCCOC)c2c1)c1OCOC Chemical compound CCc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)C3OCCOC)c2c1)c1OCOC LEMLOZUONYRJOT-LRUVZNEXSA-N 0.000 description 1
- BDUXUZGPIVJVQH-CEINQSIVSA-N CCc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)[C@H]3NCc1ccccn1)c2c1)c1O Chemical compound CCc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)[C@H]3NCc1ccccn1)c2c1)c1O BDUXUZGPIVJVQH-CEINQSIVSA-N 0.000 description 1
- XZCUZVXBIAKJOG-QBWMBKMBSA-N CCc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)[C@H]3NCc1ccccn1)c2c1)c1OCOC Chemical compound CCc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)[C@H]3NCc1ccccn1)c2c1)c1OCOC XZCUZVXBIAKJOG-QBWMBKMBSA-N 0.000 description 1
- MWXFVZDWSYGMDC-XMAZARRUSA-N CCc(cc(C(CC1)C(CC2)C3[C@@]1(C)[C@@H](CC#N)CC3)c2c1)c1O[Si+](C)(C)C(C)(C)C Chemical compound CCc(cc(C(CC1)C(CC2)C3[C@@]1(C)[C@@H](CC#N)CC3)c2c1)c1O[Si+](C)(C)C(C)(C)C MWXFVZDWSYGMDC-XMAZARRUSA-N 0.000 description 1
- UGMPGVLZEISWCJ-CTYSQQGOSA-N CCc(cc(C(CC1)C(CC2)C3[C@@]1(C)[C@@H](CCOS(N)(=O)=O)CC3)c2c1)c1OS(N)(=O)=O Chemical compound CCc(cc(C(CC1)C(CC2)C3[C@@]1(C)[C@@H](CCOS(N)(=O)=O)CC3)c2c1)c1OS(N)(=O)=O UGMPGVLZEISWCJ-CTYSQQGOSA-N 0.000 description 1
- UVSJIJJDJTZBNV-IFWOZUGISA-N C[C@](CC1)(C(CC2)C(CC3)C1c(cc1OC)c3cc1O)[C@H]2OCCO Chemical compound C[C@](CC1)(C(CC2)C(CC3)C1c(cc1OC)c3cc1O)[C@H]2OCCO UVSJIJJDJTZBNV-IFWOZUGISA-N 0.000 description 1
- DZUMTLFRSVBPNW-VYJKVFMHSA-N C[C@](CC1)(C(CC2)C(CCc3c4)C1c3ccc4O)[C@H]2NCCOC Chemical compound C[C@](CC1)(C(CC2)C(CCc3c4)C1c3ccc4O)[C@H]2NCCOC DZUMTLFRSVBPNW-VYJKVFMHSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0306717.0 | 2003-03-24 | ||
| GB0306717A GB0306717D0 (en) | 2003-03-24 | 2003-03-24 | Compound |
| GB0315885.4 | 2003-07-07 | ||
| GB0315885A GB0315885D0 (en) | 2003-07-07 | 2003-07-07 | Compound |
| PCT/GB2004/000705 WO2004085459A1 (en) | 2003-03-24 | 2004-02-20 | Oestrogen derivatives as inhibitors of steroid sulphatase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006521335A JP2006521335A (ja) | 2006-09-21 |
| JP2006521335A5 JP2006521335A5 (cg-RX-API-DMAC10.html) | 2007-03-01 |
| JP4719144B2 true JP4719144B2 (ja) | 2011-07-06 |
Family
ID=33099976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505892A Expired - Fee Related JP4719144B2 (ja) | 2003-03-24 | 2004-02-20 | ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 |
Country Status (14)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0113920D0 (en) | 2001-06-07 | 2001-08-01 | Sterix Ltd | Composition |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| WO2008090517A2 (en) * | 2007-01-26 | 2008-07-31 | Piramal Life Sciences Limited | Enriched plant extract, compound, and methods for the treatment of proliferative disorders |
| EP2149371A1 (en) | 2008-07-28 | 2010-02-03 | PregLem S.A. | Use of steroid sulfatase inhibitors for the treatment of preterm labor |
| EP2334686B1 (en) | 2008-08-28 | 2019-02-27 | President and Fellows of Harvard College | Cortistatin analogues and syntheses therof |
| JP2012524778A (ja) * | 2009-04-22 | 2012-10-18 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 血管新生阻害剤 |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| DK2935307T3 (en) | 2012-12-18 | 2018-07-30 | Univ Washington | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9365502B2 (en) | 2013-03-11 | 2016-06-14 | Washington University | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| CA2918735C (en) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| SG11201605178WA (en) | 2013-12-24 | 2016-07-28 | Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| AU2017283878A1 (en) * | 2016-06-15 | 2019-01-03 | Sony Corporation | Information processing device, observation system, observation method, and program |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス, インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| DE19723794A1 (de) * | 1997-06-06 | 1998-12-10 | Jenapharm Gmbh | Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität |
| US6288050B1 (en) * | 1997-07-18 | 2001-09-11 | Duquesne University Of The Holy Ghost | Steroid sulfatase inhibitors and methods for making and using the same |
| GB2331987B (en) * | 1997-12-04 | 2002-11-27 | Imperial College | Polycyclic sulphamate inhibitors of oestrone sulphatase |
| US6046186A (en) * | 1997-12-24 | 2000-04-04 | Sri International | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
| JP2002517449A (ja) * | 1998-06-10 | 2002-06-18 | ステリックス リミテッド | エストロンスルファターゼの阻害のための腫瘍壊死因子aおよび2−メトキシエストロン−3−o−スルファメートを有する薬学的組成物 |
| JP5042411B2 (ja) * | 1999-04-30 | 2012-10-03 | ステリックス リミテッド | 抗腫瘍剤としてのエストロン誘導体の使用 |
| JPWO2001081364A1 (ja) * | 2000-04-24 | 2004-01-08 | 協和醗酵工業株式会社 | エストラ−1,3,5(10)−トリエン誘導体 |
| CA2408751A1 (en) * | 2000-05-11 | 2001-11-15 | Robert Henry Hesse | 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity |
| CA2418479C (en) * | 2000-08-18 | 2007-12-18 | The Board Of Trustees Of The University Of Illinois | Prodrugs of betulinic acid derivatives for the treatment of cancer |
| GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
| WO2002062347A1 (en) | 2001-02-05 | 2002-08-15 | Oncology Sciences Corporation | Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis |
| GB0421106D0 (en) * | 2004-09-22 | 2004-10-27 | Sterix Ltd | Compound |
-
2004
- 2004-02-20 DE DE602004024966T patent/DE602004024966D1/de not_active Expired - Lifetime
- 2004-02-20 EA EA200501426A patent/EA011123B1/ru not_active IP Right Cessation
- 2004-02-20 EP EP04713124A patent/EP1608671B1/en not_active Expired - Lifetime
- 2004-02-20 WO PCT/GB2004/000705 patent/WO2004085459A1/en not_active Ceased
- 2004-02-20 ES ES04713124T patent/ES2339450T3/es not_active Expired - Lifetime
- 2004-02-20 AT AT04713124T patent/ATE454395T1/de not_active IP Right Cessation
- 2004-02-20 CA CA2520142A patent/CA2520142C/en not_active Expired - Fee Related
- 2004-02-20 AU AU2004224053A patent/AU2004224053B2/en not_active Ceased
- 2004-02-20 PL PL378577A patent/PL378577A1/pl not_active Application Discontinuation
- 2004-02-20 BR BRPI0408703-8A patent/BRPI0408703A/pt not_active IP Right Cessation
- 2004-02-20 DK DK04713124.8T patent/DK1608671T3/da active
- 2004-02-20 MX MXPA05010339A patent/MXPA05010339A/es active IP Right Grant
- 2004-02-20 JP JP2006505892A patent/JP4719144B2/ja not_active Expired - Fee Related
-
2005
- 2005-09-23 US US11/233,945 patent/US7893284B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004085459A1 (en) | 2004-10-07 |
| ATE454395T1 (de) | 2010-01-15 |
| EA011123B1 (ru) | 2008-12-30 |
| BRPI0408703A (pt) | 2006-03-07 |
| US7893284B2 (en) | 2011-02-22 |
| DE602004024966D1 (de) | 2010-02-25 |
| HK1082258A1 (en) | 2006-06-02 |
| AU2004224053B2 (en) | 2011-06-09 |
| EP1608671A1 (en) | 2005-12-28 |
| AU2004224053A1 (en) | 2004-10-07 |
| DK1608671T3 (da) | 2010-05-10 |
| PL378577A1 (pl) | 2006-05-02 |
| MXPA05010339A (es) | 2005-12-14 |
| US20060094696A1 (en) | 2006-05-04 |
| EA200501426A1 (ru) | 2006-06-30 |
| CA2520142A1 (en) | 2004-10-07 |
| ES2339450T3 (es) | 2010-05-20 |
| CA2520142C (en) | 2011-01-04 |
| EP1608671B1 (en) | 2010-01-06 |
| JP2006521335A (ja) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006521335A (ja) | ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 | |
| US6054446A (en) | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | |
| JP5582604B2 (ja) | アロマターゼインヒビターとしてのスルファメート基を含む1,2,4−トリアゾール誘導体 | |
| US8003783B2 (en) | 17B-hydroxysteroid dehydrogenase inhibitors | |
| JP4958377B2 (ja) | ステロイドスルファターゼのインヒビターとしてのエストロゲン−17−スルファメート | |
| JP5042411B2 (ja) | 抗腫瘍剤としてのエストロン誘導体の使用 | |
| JP4771660B2 (ja) | アロマターゼインヒビターとしてのスルファメート基を含む1,2,4−トリアゾール誘導体 | |
| JP4931312B2 (ja) | ステロイドスルファターゼのインヒビターとしてのハロゲン化スルファメート−、ホスホネート−、チオホスホネート−、スルホネート−、およびスルホンアミド−化合物 | |
| JP2003519658A (ja) | ステロイド構造を含む薬学的組成物およびそれらの使用 | |
| JP4553586B2 (ja) | ステロイドスルファターゼを阻害するための、ステロイド化合物 | |
| CA2576614A1 (en) | 2-substituted estrogen sulphamates for inhibition of steroid sulphatase | |
| HK1082258B (en) | Oestrogen derivatives as inhibitors of steroid sulphatase | |
| CN100384868C (zh) | 类固醇硫酸酯酶抑制剂的雌激素衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100903 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110128 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110217 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110310 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110401 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140408 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |